Allied Market Research published a report, titled, “Human Papillomavirus Vaccine (HPV) Market by By Type (Tetravalent, Nonavalent, Bivalent), by By Disease Indication (Cervical Cancer, Anal Cancer, Vulvar & Vaginal Cancer, Penile Cancer, Oropharyngeal Cancer, Others), by By Industry Vertical (Public and Private Alliances, Government Entities, Physicians, Others): Global Opportunity Analysis and Industry Forecast, 2021-2030.” According to the report, the global human papillomavirus vaccine market was estimated at $3.9 billion in 2021, and is anticipated to hit $10.8 billion by 2030, registering a CAGR of 12.4% from 2022 to 2030.
Download Report (245 Pages PDF with Insights, Charts, Tables, Figures): https://www.alliedmarketresearch.com/request-sample/14697
Covid-19 scenario-
- Ever since the Covid-19 pandemic has broken out, vaccine producers and other scientists have been continuously working on the development of HPV vaccines as well as COVID-19 viral symptoms, which has impacted the global papillomavirus vaccine market positively.
- Even during the lockdown and the government controls set in response to the pandemic, most healthcare personnel were seen to carry out their tasks, and companies were also spending heavily on vaccine development.
Scope of the Report: –
|
Report Attribute |
Details |
|
Revenue forecast in 2030 |
$ 4.4 billion |
|
Growth rate |
CAGR of 3.8% from 2022 to 2031 |
|
Forecast period |
2022 – 2031 |
|
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
|
Regional scope |
North America, Europe, Asia Pacific, Latin America, MEA |
|
Country scope |
U.S., Canada, Germany, U.K., France, Italy, Spain, Japan, China, India, South Korea, Australia, Brazil, Mexico, South Africa, Saudi Arabia |
|
Key companies profiled |
Bayer AG, CooperSurgical Inc, DKT International, Mona Lisa NV, Pregna International Limited, Prosan International BV, Abviee Inc, Eurogine, S.L., Viatris Inc, Mona Lisa N.V. Access Table PDF |
Specific Requirement on COVID-19? Ask to Our Industry Expert: https://www.alliedmarketresearch.com/request-for-customization/14697?reqfor=covid
Based on type, the tetravalent segment accounted for more than three-fourths of the global human papillomavirus vaccine market share in 2021, and is anticipated to rule the roost by 2030. This is because the tetravalent human papillomavirus vaccine protects against HPV types 6, 11, 16, and 18 infections. The nonavalent segment, however, would cite the fastest CAGR of 13.9% throughout the forecast period.
Q1. What are the driving factors and opportunities in the global human papillomavirus vaccine market?
Q2. What current trends will influence the human papillomavirus vaccine market in the next few years?
Q3. Which regions will provide more business opportunities for global human papillomavirus vaccine in future?
Q4. What are the key growth strategies of global human papillomavirus vaccine market players?
Q5. Who are the leading market players active in the human papillomavirus vaccine market?
Inquire Before Buying : https://www.alliedmarketresearch.com/purchase-enquiry/14697
𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐢𝐧 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲:
𝐀𝐧𝐭𝐢𝐧𝐮𝐜𝐥𝐞𝐚𝐫 𝐀𝐧𝐭𝐢𝐛𝐨𝐝𝐲 𝐓𝐞𝐬𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡, 2031
𝐒𝐢𝐧𝐠𝐥𝐞 𝐂𝐞𝐥𝐥 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡, 2031
𝐈𝐦𝐦𝐮𝐧𝐨𝐡𝐢𝐬𝐭𝐨𝐜𝐡𝐞𝐦𝐢𝐬𝐭𝐫𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡, 2031
𝐂𝐨𝐦𝐩𝐨𝐮𝐧𝐝𝐢𝐧𝐠 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐢𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡, 2031
𝐓𝐞𝐧𝐝𝐨𝐧 𝐑𝐞𝐩𝐚𝐢𝐫 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡, 2031
𝐎𝐫𝐭𝐡𝐨𝐛𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐎𝐮𝐭𝐥𝐨𝐨𝐤 – 20231
Hospital Beds Market Global Opportunity Analysis and Industry Forecast to 2031